Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Jörn M. Schattenberg is a Professor of Medicine and Director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and at the Tulane University in New Orleans (US). He completed his post-doctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signaling pathways involved in the pathophysiology of acute and chronic liver injury with a special focus on metabolic liver disease and non-alcoholic steatohepatitis (NASH).
He is board-certified in Internal Medicine and Gastroenterology & Hepatology and Infectious Disease. He built up the Metabolic Liver Research Program that focuses on translational sciences and clinical trials. Additionally, he heads a liver research laboratory focusing on clinical and experimental aspects of liver injury, the development of therapeutic intervention and novel biomarkers in liver disease.
Professor Schattenberg is a member of the executive committee of the LITMUS consortium, member of the Scientific Committee of the United European Gastroenterology (UEG), member of the Policy and Public Health Committee of the European Association for the Study of the Liver (EASL) and a member of the Editorial Board of Hepatology and the Alimentary Pharmacology & Therapeutics.
Lise Lotte Gluud
University of Copenhagen, Copenhagen, Denmark
Prof Lise L Gluud is Professor of lifestyle associated liver diseases at the University of Copenhagen and a consultant Gastroenterologist at the Gastro Unit, which is the largest gastroenterology department in Denmark. She is a founding member of the Centre for Liver Disease in Copenhagen (CLIC) and the Centre for Obesity Amager and Hvidovre Hospital (ACAHH). Her main research interests include non-alcoholic steatohepatitis as well as cirrhosis-related complications. Publications include both clinical as well as pathophysiological studies with 162 Medline Indexed publications and a H index of 66. Prof Gluud’s qualifications include: Specially Appointed Named Person at the Faculty of Health and Medical Sciences, University of Copenhagen, Member of the Specialist Groups at the Danish National Genomic Centre; Chairman of the National Clinical Guideline for the Management of patients with NAFLD; and Chairman of the Danish Association of Gastroenterology and Hepatology (DSGH) Research Committee.
Read full bio
Quentin Anstee
Newcastle University, Newcastle, UK
Prof Quentin M. Anstee is Chair of Experimental Hepatology and Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, UK. A practicing clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital, where he leads one of the largest Non-Alcoholic Fatty Liver Disease (NAFLD) clinical services in the U.K. Prof Anstee’s translational research has made major contributions across the pathophysiology, natural history, diagnosis and treatment of NAFLD. His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. He coordinates two major international research consortia that are studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020, 2015-2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2, 2017-2022). He has established the European NAFLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for NAFLD. He is an Associate Editor of the Journal of Hepatology.
Read full bio